Antibody Specificity, Affinity and Kinetics in a Single Experiment
The emerging non-traditional antibody formats are often more efficacious, reaching new therapeutic targets including crossing the blood-brain barrier. Formats that retain the basic structure of IgGs may inherit their pharmacokinetic properties but lack the Fc-part of the antibody and can have shorter half-lives.
The smaller antibody formats such as single-chain fragment variables, nanobodies or other scaffolds that can reach hidden targets or act as intrabodies to target intracellular antigens must strike a balance between efficacy and half-life.
Watch this webinar to learn more about:
- Applications for screening and characterizing antibody and antibody fragments
- A label-free technology which uses surface plasmon resonance (a biophysical technology) for characterizing antibodies
Keynote Speaker
Anna Moberg
Section Manager
Biacore Applications & Consumables, Cytiva
Brought to you by
Watch this Webinar NOW, Access Below
Information you provide will be shared with the sponsors for this content.
Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
